Radioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer

This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111ln (2 mCi) and injected into 19 patients suspected...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 1997-04, Vol.88 (4)
Main Authors: Yong‐Suk Chung, Sawada, Tetsuji, Kondo, Yasuyuki, Hirayama, Koji, Inui, Akimasa, Yamashita, Yoshito, Nakata, Bunzo, Okamura, Terue, Ochi, Hironobu, Ho, Jenny J L, Kim, Young S, Sowa, Michio
Format: Article
Language:English
Subjects:
Carcinoma
Monoclonal antibodies
Mucin
Pancreatic cancer
Pancreatitis
Patients
Surgery
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 4
container_start_page
container_title Cancer science
container_volume 88
creator Yong‐Suk Chung
Sawada, Tetsuji
Kondo, Yasuyuki
Hirayama, Koji
Inui, Akimasa
Yamashita, Yoshito
Nakata, Bunzo
Okamura, Terue
Ochi, Hironobu
Ho, Jenny J L
Kim, Young S
Sowa, Michio
description This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111ln (2 mCi) and injected into 19 patients suspected of having pancreatic cancer. Planar scintigrams were taken 3 days post–infusion. As for final diagnoses after surgery, 14 cases were pancreatic cancer, and one case each was chronic pancreatitis, neurilem–moma, islet cell carcinoma, cholangioma, and apparent absence of suspected recurrent lesion of pancreatic cancer. Of 14– patients with pancreatic cancer, RAID was positive in 10 cases (71.4%). Cases other than pancreatic cancer were all negative, so the specificity was 100%. These results demonstrate that RAID using 111In–Nd2 can be useful in differentiating exocrine pancreatic cancer from benign conditions and other types of carcinomas in the pancreatoduodenal regions.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2399633395</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399633395</sourcerecordid><originalsourceid>FETCH-proquest_journals_23996333953</originalsourceid><addsrcrecordid>eNqNjMFqAjEURYNU0Fb_4UHXA5nJOJKlSEtdVES6l0zyxAzxPTvJIO76D_6hX-JQ-wFd3cPl3DsQ41yVOptLWT398jzTUhUj8RxjI6WqSl2OBW6N8-yPx47YYUKbPBOcfTpAnuewotvPNZgaAzr4ZGIbmEyABSVfs7vA2hXgCTYmeaQUH8uNIdtiX1lY9ojtRAz3JkSc_uWLeH1_-1p-ZKeWvzuMaddw1_bHcVcorSullJ6p_1l3z59ITw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2399633395</pqid></control><display><type>article</type><title>Radioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Yong‐Suk Chung ; Sawada, Tetsuji ; Kondo, Yasuyuki ; Hirayama, Koji ; Inui, Akimasa ; Yamashita, Yoshito ; Nakata, Bunzo ; Okamura, Terue ; Ochi, Hironobu ; Ho, Jenny J L ; Kim, Young S ; Sowa, Michio</creator><creatorcontrib>Yong‐Suk Chung ; Sawada, Tetsuji ; Kondo, Yasuyuki ; Hirayama, Koji ; Inui, Akimasa ; Yamashita, Yoshito ; Nakata, Bunzo ; Okamura, Terue ; Ochi, Hironobu ; Ho, Jenny J L ; Kim, Young S ; Sowa, Michio</creatorcontrib><description>This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111ln (2 mCi) and injected into 19 patients suspected of having pancreatic cancer. Planar scintigrams were taken 3 days post–infusion. As for final diagnoses after surgery, 14 cases were pancreatic cancer, and one case each was chronic pancreatitis, neurilem–moma, islet cell carcinoma, cholangioma, and apparent absence of suspected recurrent lesion of pancreatic cancer. Of 14– patients with pancreatic cancer, RAID was positive in 10 cases (71.4%). Cases other than pancreatic cancer were all negative, so the specificity was 100%. These results demonstrate that RAID using 111In–Nd2 can be useful in differentiating exocrine pancreatic cancer from benign conditions and other types of carcinomas in the pancreatoduodenal regions.</description><identifier>ISSN: 1347-9032</identifier><identifier>EISSN: 1349-7006</identifier><language>eng</language><publisher>Tokyo: John Wiley &amp; Sons, Inc</publisher><subject>Carcinoma ; Monoclonal antibodies ; Mucin ; Pancreatic cancer ; Pancreatitis ; Patients ; Surgery</subject><ispartof>Cancer science, 1997-04, Vol.88 (4)</ispartof><rights>Copyright John Wiley &amp; Sons, Inc. Apr 1997</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2399633395/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2399633395?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,37012,44590,75126</link.rule.ids></links><search><creatorcontrib>Yong‐Suk Chung</creatorcontrib><creatorcontrib>Sawada, Tetsuji</creatorcontrib><creatorcontrib>Kondo, Yasuyuki</creatorcontrib><creatorcontrib>Hirayama, Koji</creatorcontrib><creatorcontrib>Inui, Akimasa</creatorcontrib><creatorcontrib>Yamashita, Yoshito</creatorcontrib><creatorcontrib>Nakata, Bunzo</creatorcontrib><creatorcontrib>Okamura, Terue</creatorcontrib><creatorcontrib>Ochi, Hironobu</creatorcontrib><creatorcontrib>Ho, Jenny J L</creatorcontrib><creatorcontrib>Kim, Young S</creatorcontrib><creatorcontrib>Sowa, Michio</creatorcontrib><title>Radioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer</title><title>Cancer science</title><description>This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111ln (2 mCi) and injected into 19 patients suspected of having pancreatic cancer. Planar scintigrams were taken 3 days post–infusion. As for final diagnoses after surgery, 14 cases were pancreatic cancer, and one case each was chronic pancreatitis, neurilem–moma, islet cell carcinoma, cholangioma, and apparent absence of suspected recurrent lesion of pancreatic cancer. Of 14– patients with pancreatic cancer, RAID was positive in 10 cases (71.4%). Cases other than pancreatic cancer were all negative, so the specificity was 100%. These results demonstrate that RAID using 111In–Nd2 can be useful in differentiating exocrine pancreatic cancer from benign conditions and other types of carcinomas in the pancreatoduodenal regions.</description><subject>Carcinoma</subject><subject>Monoclonal antibodies</subject><subject>Mucin</subject><subject>Pancreatic cancer</subject><subject>Pancreatitis</subject><subject>Patients</subject><subject>Surgery</subject><issn>1347-9032</issn><issn>1349-7006</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNjMFqAjEURYNU0Fb_4UHXA5nJOJKlSEtdVES6l0zyxAzxPTvJIO76D_6hX-JQ-wFd3cPl3DsQ41yVOptLWT398jzTUhUj8RxjI6WqSl2OBW6N8-yPx47YYUKbPBOcfTpAnuewotvPNZgaAzr4ZGIbmEyABSVfs7vA2hXgCTYmeaQUH8uNIdtiX1lY9ojtRAz3JkSc_uWLeH1_-1p-ZKeWvzuMaddw1_bHcVcorSullJ6p_1l3z59ITw</recordid><startdate>19970401</startdate><enddate>19970401</enddate><creator>Yong‐Suk Chung</creator><creator>Sawada, Tetsuji</creator><creator>Kondo, Yasuyuki</creator><creator>Hirayama, Koji</creator><creator>Inui, Akimasa</creator><creator>Yamashita, Yoshito</creator><creator>Nakata, Bunzo</creator><creator>Okamura, Terue</creator><creator>Ochi, Hironobu</creator><creator>Ho, Jenny J L</creator><creator>Kim, Young S</creator><creator>Sowa, Michio</creator><general>John Wiley &amp; Sons, Inc</general><scope>8FE</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>19970401</creationdate><title>Radioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer</title><author>Yong‐Suk Chung ; Sawada, Tetsuji ; Kondo, Yasuyuki ; Hirayama, Koji ; Inui, Akimasa ; Yamashita, Yoshito ; Nakata, Bunzo ; Okamura, Terue ; Ochi, Hironobu ; Ho, Jenny J L ; Kim, Young S ; Sowa, Michio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_23996333953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Carcinoma</topic><topic>Monoclonal antibodies</topic><topic>Mucin</topic><topic>Pancreatic cancer</topic><topic>Pancreatitis</topic><topic>Patients</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yong‐Suk Chung</creatorcontrib><creatorcontrib>Sawada, Tetsuji</creatorcontrib><creatorcontrib>Kondo, Yasuyuki</creatorcontrib><creatorcontrib>Hirayama, Koji</creatorcontrib><creatorcontrib>Inui, Akimasa</creatorcontrib><creatorcontrib>Yamashita, Yoshito</creatorcontrib><creatorcontrib>Nakata, Bunzo</creatorcontrib><creatorcontrib>Okamura, Terue</creatorcontrib><creatorcontrib>Ochi, Hironobu</creatorcontrib><creatorcontrib>Ho, Jenny J L</creatorcontrib><creatorcontrib>Kim, Young S</creatorcontrib><creatorcontrib>Sowa, Michio</creatorcontrib><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer science</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yong‐Suk Chung</au><au>Sawada, Tetsuji</au><au>Kondo, Yasuyuki</au><au>Hirayama, Koji</au><au>Inui, Akimasa</au><au>Yamashita, Yoshito</au><au>Nakata, Bunzo</au><au>Okamura, Terue</au><au>Ochi, Hironobu</au><au>Ho, Jenny J L</au><au>Kim, Young S</au><au>Sowa, Michio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer</atitle><jtitle>Cancer science</jtitle><date>1997-04-01</date><risdate>1997</risdate><volume>88</volume><issue>4</issue><issn>1347-9032</issn><eissn>1349-7006</eissn><abstract>This report summarizes results from an initial clinical evaluation of radioimnumodetection (RAID) in patients with pancreatic cancer using murine monoclonal antibody Nd2, directed against mucins from pancreatic cancer.Nd2 (2 mg) was labeled with 111ln (2 mCi) and injected into 19 patients suspected of having pancreatic cancer. Planar scintigrams were taken 3 days post–infusion. As for final diagnoses after surgery, 14 cases were pancreatic cancer, and one case each was chronic pancreatitis, neurilem–moma, islet cell carcinoma, cholangioma, and apparent absence of suspected recurrent lesion of pancreatic cancer. Of 14– patients with pancreatic cancer, RAID was positive in 10 cases (71.4%). Cases other than pancreatic cancer were all negative, so the specificity was 100%. These results demonstrate that RAID using 111In–Nd2 can be useful in differentiating exocrine pancreatic cancer from benign conditions and other types of carcinomas in the pancreatoduodenal regions.</abstract><cop>Tokyo</cop><pub>John Wiley &amp; Sons, Inc</pub><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1347-9032
ispartof Cancer science, 1997-04, Vol.88 (4)
issn 1347-9032
1349-7006
language eng
recordid cdi_proquest_journals_2399633395
source Open Access: PubMed Central; Publicly Available Content Database
subjects Carcinoma
Monoclonal antibodies
Mucin
Pancreatic cancer
Pancreatitis
Patients
Surgery
title Radioimmunodetection with 111 In–labeled Monoclonal Antibody Nd2 in Patients with Pancreatic Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T02%3A36%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radioimmunodetection%20with%20111%20In%E2%80%93labeled%20Monoclonal%20Antibody%20Nd2%20in%20Patients%20with%20Pancreatic%20Cancer&rft.jtitle=Cancer%20science&rft.au=Yong%E2%80%90Suk%20Chung&rft.date=1997-04-01&rft.volume=88&rft.issue=4&rft.issn=1347-9032&rft.eissn=1349-7006&rft_id=info:doi/&rft_dat=%3Cproquest%3E2399633395%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_journals_23996333953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2399633395&rft_id=info:pmid/&rfr_iscdi=true